QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Trastuzumab Classification, Mechanism, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Trastuzumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which feature most helps distinguish an immediate infusion reaction from delayed pulmonary toxicity?

The patient's HER2 score alone Temporal relationship to administration together with clinical phenotype, oxygenation, imaging, and response to intervention The brand name without dose or route Whether the tumour is primary or metastatic, without clinical findings

Question 2 of 10 What is the most appropriate interpretation of HER2 status from a single biopsy of a heterogeneous metastatic cancer?

It is a perfect representation of every tumour site throughout the disease course It is a spatial and temporal sample that may not fully represent other lesions or later disease It should always override all subsequent test results It is irrelevant once treatment has started

Question 3 of 10 Which statement best explains why HER2 status is both an efficacy determinant and a safety-system concern?

HER2 testing determines whether the patient is likely to benefit, and an erroneous result can cause ineffective exposure or deny effective treatment HER2 testing is used only to predict infusion reactions HER2 status determines the batch number that must be reported HER2 testing is optional because trastuzumab benefits all solid tumours equally

Question 4 of 10 What is the principal pharmacovigilance implication of trastuzumab being a humanised rather than fully murine antibody?

Humanisation eliminates all immunogenicity Humanisation reduces the proportion of non-human sequence while retaining target recognition and human Fc effector function Humanisation prevents binding to Fc gamma receptors Humanisation converts the antibody into a biosimilar

Question 5 of 10 Why is it inadequate in pharmacovigilance to record only 'trastuzumab' without the precise medicinal product?

Because all trastuzumab products have completely unrelated molecular targets Because unconjugated trastuzumab, biosimilars, and trastuzumab-containing conjugates can differ in formulation, payload, route, and safety profile Because the active substance name is not relevant to causality assessment Because trastuzumab products are chemically identical and therefore cannot be distinguished clinically

Question 6 of 10 Why can pregnancy remain relevant to a trastuzumab safety assessment after the last dose?

Because trastuzumab is eliminated instantly but permanently alters fetal DNA Because the antibody has a long elimination phase and residual exposure may overlap with conception or later pregnancy Because pregnancy changes the HER2 test result in every patient Because only exposure during the first treatment cycle matters

Question 7 of 10 Which information is particularly important in a pregnancy exposure case involving trastuzumab?

Only the trimester in which exposure occurred Last menstrual period, dose dates, estimated conception, fetal and amniotic-fluid findings, co-treatments, outcome, and neonatal follow-up Only the maternal HER2 score Only whether the pregnancy reached delivery

Question 8 of 10 Which medication error requires specific product-level investigation because shared naming may conceal major pharmacological differences?

Recording a patient's body temperature in Celsius Selecting trastuzumab emtansine or trastuzumab deruxtecan when unconjugated trastuzumab was intended Using a validated HER2 assay Documenting the infusion start time

Question 9 of 10 Which statement best reflects the regulatory significance of trastuzumab's movement from metastatic to early breast-cancer treatment?

The safety framework became less important because early disease is cured The exposed population and benefit-risk context changed, increasing the importance of preventing recurrence while protecting patients with long expected survival from cardiac harm The need for HER2 testing disappeared in early disease Only the manufacturing process changed; clinical pharmacovigilance requirements remained identical

Question 10 of 10 A gastric-cancer HER2 result is being interpreted using breast-cancer scoring rules without considering tumour-specific criteria. What is the most appropriate interpretation?

This is acceptable because HER2 expression has identical distribution and interpretation across tumour types This may create diagnostic misclassification because staining patterns and validated criteria can be tumour-context dependent This affects only efficacy analysis and has no safety relevance This is required whenever the tumour has basolateral staining

QPPV.com

Knowledge Assessment: Trastuzumab Classification, Mechanism, Safety and Pharmacovigilance

Cookie Settings